Anilocus delivers specialized preclinical contract research organization services to New York’s thriving biotech ecosystem, providing comprehensive research support with local accessibility and regulatory expertise to accelerate drug discovery in America’s fastest-growing life sciences hub.
In vivo pilot studies test experimental feasibility and refine methodologies before conducting larger animal studies, providing essential preliminary data while minimizing animal use through careful planning.
Animal researchers must calculate precise sample sizes using statistical methods to ensure studies detect meaningful effects while minimizing animal use and meeting ethical requirements for publication.
Researchers submitting samples to Anilocus flow cytometry services must prepare single-cell suspensions with >90% viability, ship at room temperature within 48 hours, and coordinate with our laboratory to ensure optimal analysis.
Artificial intelligence is revolutionizing medical imaging by analyzing X-rays, MRIs, and CT scans with promising results in some areas while facing significant challenges in others, helping doctors detect diseases more efficiently when properly implemented.
Clinical trials advance through four phases testing drug safety and effectiveness, with only 13.8% of treatments successfully reaching FDA approval after rigorous testing in thousands of patients over multiple years.
Global pharmaceutical pipeline shows 12,500 drugs in preclinical development while market grows to $71 billion, with contract research organizations like Anilocus accelerating breakthrough therapies from discovery to clinical trials through specialized services.
German and South African researchers tested AI explanation tools used in medical imaging, finding that while some methods like ScoreCAM effectively highlight disease-relevant areas in brain scans and X-rays, others fail reliability tests. Surprisingly, random highlighting sometimes outperformed sophisticated AI explanation methods, raising concerns about trustworthiness before clinical deployment.
Mouse study design requires systematic planning to generate reliable, reproducible research data that meets regulatory standards. Poor planning leads to invalid results, wasted resources, and potential animal welfare issues. Before starting, researchers must assess their readiness by ensuring institutional approval pathways, basic research experience, and access to animal facilities. This
Anilocus provides comprehensive safety biomarker analysis including molecular, cellular, and protein-based markers for early detection of organ toxicity and adverse effects. Our capabilities include qPCR analysis, flow cytometry, Western blot, and specialized tissue analysis to identify safety signals and support regulatory submissions for drug development programs.
Bold ideas and breakthrough research. Expert analysis on the innovations and drug development for the most important people in the world: patients.
Use this form to send your questions to our research team about our preclinical contract research services.
We are here to help!
